View Older Stories View More Recent Stories
-
Lumos Pharma to Participate in November Investor Conferences
-
Ready Launches Virtual Mental Health Services as Part of Unique At-Home Care Model
-
Lumos Pharma to Report Third Quarter 2020 Financial Results and Host a Conference Call on November 10, 2020
-
Lumos Pharma to Report Third Quarter 2020 Financial Results and Host a Conference Call on November 10, 2020
-
Dracen Pharmaceutical's DRP-104 Granted U.S. FDA Fast Track Designation for the treatment of Non-Small Cell Lung Cancer
-
Miami Residents to Receive COVID-19 Testing and Medical Care from On-Demand Healthcare Service Ready
-
The New York Academy Of Medicine Welcomes New Board Chair Dr. Wayne Riley, President Of SUNY Downstate
-
InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing
-
Nuvation Bio and Panacea Announce Business Combination Agreement, Creating a Publicly Listed Leader in Oncology Drug Development
-
Nuo Therapeutics Announces Recapitalization and Exchange Agreement that Simplifies Capital Structure
-
Curation Health Announces Series A Financing from Deerfield Management Company and WindRose Health Investors
-
Olema Oncology Raises $85 Million in Series C Financing to Advance Clinical Development of OP-1250 in Breast Cancer
-
Dracen Pharmaceuticals Announces the Initiation of First-in-human Study of DRP-104 in Adult Patients With Advanced Solid Tumors
-
V-Wave Completes Financing of Up to $98M from Syndicate of Leading Global Healthcare Investors
-
Bridge Medicines Adds Small Molecule Inhibitors of Activated Factor XII to Pipeline
-
On-demand Healthcare Service, Ready, Raises $54 Million in Series C Financing
-
Element Science Names Zubin J. Eapen, MD as Chief Medical Officer
-
Blade Therapeutics Reaches Enrollment Goal for Phase 2 Study of Lead Investigational Therapy BLD-2660 in Treating Patients With COVID-19 Pneumonia
-
Deerfield Healthcare Technology Acquisitions Corp. Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing on or about September 14, 2020
-
BioNJ Announces Lineup for Virtual BioPartnering Conference
-
Lumos Pharma to Participate in Upcoming Investor Conferences
-
Lumos Pharma to Participate in Upcoming Investor Conferences
-
Oxford Finance Provides Credit Facility to Brain Injury Rehab Provider ReMed Holdings, LLC
-
Overdose Crisis Endures, Yet Few People Receive Existing Effective Treatment
-
Form 13F-HR DEERFIELD MANAGEMENT For: Jun 30
-
Lumos Pharma Reports Second Quarter 2020 Results and Provides Update on Clinical and Corporate Activities
-
Lumos Pharma Reports Second Quarter 2020 Results and Provides Update on Clinical and Corporate Activities
-
Blade Therapeutics Updates Enrollment Progress for Phase 2 Study of Lead Investigational Therapy BLD-2660 in Treating Patients with COVID-19 Pneumonia
-
Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results
-
Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results
-
AVEO Oncology Reports Second Quarter 2020 Financial Results and Provides Business Update
-
BioSpecifics Reports Second Quarter 2020 Financial and Operating Results
-
Nuvo Pharmaceuticals® Announces Second Quarter 2020 Results
-
Blade Therapeutics Appoints Accomplished Biopharmaceutical Executive, Mark Timney, as Chairman of the Board
-
Quartet Health Partners With SilverCloud Health to Expand Access to Mental Health Care Options Nationwide
-
Melinta Therapeutics Announces Appointment of Christine Ann Miller as President and Chief Executive Officer
-
Melinta Therapeutics Announces Appointment of Christine Ann Miller as President and Chief Executive Officer
-
Form SC 13D Deerfield Healthcare Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Sema4 Closes $121 Million Series C Led by BlackRock Funds
-
Lumos Pharma to Report Second Quarter 2020 Financial Results and Host a Conference Call on August 13, 2020
-
Lumos Pharma to Report Second Quarter 2020 Financial Results and Host a Conference Call on August 13, 2020
-
Lumos Pharma, Inc. (LUMO) Sells Priority Review Voucher (PRV) to Merck at $100M Valuation
-
Lumos Pharma Announces Sale of Priority Review Voucher
-
Lumos Pharma Announces Sale of Priority Review Voucher
-
Deerfield Healthcare Technology Acquisitions Corp. Announces Closing of $143.75 Million Initial Public Offering
-
UCLB and Apollo Therapeutics secure first out-licensing deal to Deerfield, a leading U.S. healthcare investment firm
-
BioSpecifics Appoints Alex Monteith as Chief Business Officer
-
IPO of SPAC Deerfield Healthcare Technology Acquisitions (DFHT) (DFHTU) Opens Modestly Higher
-
Deerfield Healthcare Technology Acquisitions Corp. (DFHT) Prices 12.5M Unit IPO at $10/Unit
-
Deerfield Healthcare Technology Acquisitions Corp. Announces Pricing of $125 Million Initial Public Offering

